PlumX Metrics
Embed PlumX Metrics

Efficacy of 177 Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, ISSN: 2542-4548, Vol: 5, Issue: 1, Page: 236-240
2021
  • 9
    Citations
  • 0
    Usage
  • 19
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Case Description

A 62-year-old man presented with a history of atypical meningioma (World Health Organization grade II) and recurrent as anaplastic meningioma (World Health Organization grade III). His previous treatments included multiple surgical resections, fractionated radiation therapy, stereotactic radiosurgery, everolimus/octreotide long-acting release, bevacizumab, and hydroxyurea. Magnetic resonance imaging revealed rapid volumetric progression over the prior 9 months, with a near tripling in size from 29.9 cm 3 to 80.4 cm 3. Indium In 111 octreotide scanning confirmed the presence of somatostatin receptors within the tumor. Lutetium Lu 177 dotatate was administered intravenously at a dose of 200 mCi per dose every 8 weeks for 4 cycles. Treatment was tolerated very well, with no notable adverse events. Tumor volume initially increased to 98.3 cm 3 after cycle 1 of treatment and subsequently decreased to 91.2 cm 3 after cycle 2. Eight months after treatment onset, the tumor volume remained stable (93.4 cm 3 ).

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know